Close Menu

NEW YORK (GenomeWeb News) – Promega today announced that it has inked an alliance with Puracyp, under which the firms are combining their cell line and assay technologies in an offering to researchers.

The collaboration intends to provide all-inclusive kits for nuclear receptor activation, P450 metabolism, and cellular toxicity research in the drug development process. It combines Puracyp's nuclear receptor expressing cell lines with Promega's assay and detection technologies for bioluminescent reporters, cell viability, and P450 metabolism assays.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.